drugset
drugset / Trial / NCT06995677

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677 ↗

Phase 2 Recruiting 90 enrolled Tyra Biosciences, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Timeline

Start
2025-06-27
Primary completion
2028-02
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TYRA-300 Unknown 50 mg Oral
Subject TYRA-300 Unknown 60 mg Oral

Indications

non-invasive bladder urothelial carcinoma